Serum osteoprotegerin and soluble receptor activator of nuclear factor κB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study

Metabolism: Clinical and Experimental

Volumn 56, Issue 5, 2007, Pages 699-707

  Giusti, Massimo ^a   Cecoli, Francesca ^a   Fazzuoli, Laura ^a   De Franchis, Vincenzina ^a   Ceresola, Enrica ^a   Ferone, Diego ^a   Mussap, Michele ^a   Minuto, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; LT 4; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; THYROGLOBULIN; THYROTROPIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANAMNESIS; ARTICLE; BODY MASS; BONE METABOLISM; CANCER PATIENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; FEMALE; FREE THYROXINE INDEX; GENE REPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PATHOLOGY; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THYROID CARCINOMA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE AND BONES; CALCIUM; CASE-CONTROL STUDIES; COHORT STUDIES; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHORUS; RANK LIGAND; THYROID HORMONES; THYROID NEOPLASMS; THYROTROPIN; THYROXINE;

EID: 34147170371     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.01.004     Document Type: Article

References (55)

1. Simonet W.S., Lacey D.L., Dunstan C.R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
2. Yasuda H., Shima N., Nakagawa N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin: a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 (1998) 1329-1337
3. Wong B.R., Josien R., Lee S.Y., et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186 (1997) 2075-2080
4. Lacey D.L., Timms E., Tan H.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
5. Yun T.J., Chaudhary P.M., Shu G.L., et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 161 (1998) 6113-6121
6. Hofbauer L.C., Kluger S., Kuhne C.A., et al. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. J Cell Biochem 86 (2002) 642-650
7. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95 (1998) 3597-3602
8. Emery J.G., McDonnel P., Burke M.B., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273 (1998) 14363-14367
9. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268
10. Rogers A., and Eastell R. Review: circulating osteoprotegerin and receptor activator of nuclear factor kB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90 (2005) 6323-6331
11. Burgess T.L., Qian Y., Kaufman S., et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145 (1999) 527-538
12. Fujikawa Y., Sabokbar A., Neale S.D., Itonaga I., Torisu T., and Athanasou N.A. The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6 and -11, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells. Bone 28 (2001) 261-267
13. Nakagawa N., Kinosaki M., Yamaguchi K., et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253 (1998) 395-400
14. Hsu H., Lacey D.L., Dunstan C.R., et al. Tumor necrosis factor receptor family member RANK mediates the osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96 (1999) 3540-3545
15. Kong Y.Y., Yoshida H., Sarosi I., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
16. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109 (2004) 175-180
17. Hofbauer L.C., and Heufelder A.E. The role of osteoprotegerin and receptor activator of nuclear factor-kB ligand in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 85 (2000) 2355-2363
18. Hofbauer L.C., Neubauer A., and Heufelder A.E. Receptor activator of nuclear factor-kB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92 (2001) 460-470
19. Kong Y.Y., Boyle W.J., and Penninger J.M. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today 21 (2000) 495-502
20. Bekker P.J., Holloway D., Nakanishi A., Arrighu M., Leese P.T., and Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 14 (2001) 518-527
21. Isaia G.C., Roggia C., Gola D., et al. Bone turnover in hyperthyroidism before and after thyrostatic management. J Endocrinol Invest 23 (2000) 727-731
22. Amato G., Mazziotti G., Sorvillo F., et al. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 35 (2004) 785-791
23. Guang-da X., Hui-ling S., Zhi-song C., and Lin-shuang Z. Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. J Clin Endocrinol Metab 90 (2005) 5765-5768
24. Nagasaki T., Inaba M., Jono S., et al. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Eur J Endocrinol 152 (2005) 347-353
25. Bauer D.C., Ettinger B., Nevitt M.C., and Stone K.L. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med 134 (2001) 561-568
26. Reverter J.L., Holgado S., Alonso N., Salinas I., Granada M.L., and Sanmarti A. Lack of deleterious effect on bone mineral density of long-term thyroxine suppressive therapy for differentiated thyroid carcinoma. Endocr Relat Cancer 12 (2005) 973-981
27. Lee W.Y., Oh K.W., Rhee E.J., et al. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Arch Med Res 37 (2006) 511-516
28. Jodar E., Begona Lopez M., Garcia L., et al. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine: evolution of axial and appendicular bone mass. Osteoporos Int 8 (1998) 311-316
29. Sijanovic S., and Karner I. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone. Medscape Womens Health 6 (2001) 3
30. Mazokopakis E.E., Starakis I.K., Papadomanolaki M.G., Batistakis A.G., and Papadakis J.A. Changes of bone mineral density in pre-menopausal women with differentiated thyroid cancer receiving l-thyroxine suppressive therapy. Curr Med Res Opin 22 (2006) 1369-1373
31. Chen C.H., Chen J.F., Yang B.Y., et al. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma. J Formos Med Assoc 103 (2004) 442-447
32. Sajjinaanont T., Rajchadara S., Sriassawaamorn N., and Panichkul S. The comparative study of bone mineral density between premenopausal women receiving long-term suppressive doses of levothyroxine for well-differentiated thyroid cancer with healthy premenopausal women. J Med Assoc Thai 88 Suppl 3 (2005) S71-S76
33. Heijckmann A.C., Huijberts M.S., Geusens P., de Vries J., Menheere P.P., and Wolffenbuttel B.H. Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive l-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol 153 (2005) 23-29
34. Varga F., Spitzer S., and Klaushofer K. Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype. Calcif Tissue Int 74 (2004) 382-387
35. Yano K., Tsuda E., Washida N., et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor. Increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 14 (1999) 518-527
36. Ueland T., Bollerslev J., Godang K., Muller F., Froland S.S., and Aukrust P. Increased serum oteoprotegerin in disorders characterized by persistent immune activation of glucocorticoid excess-possible role in bone homeostasis. Eur J Endocrinol 145 (2001) 685-690
37. Canalis E. Mechanism of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 15 (2003) 454-457
38. Olkawa M., Kushida K., Takahashi M., et al. Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time. Clin Endocrinol 50 (1999) 171-176
39. Akalin A., Colak O., Alatas O., and Efe B. Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol 57 (2002) 125-129
40. Siddiqi A., Monson J.P., Wood D.F., Besser G.M., and Burrin J.M. Serum cytokines in thyrotoxicosis. J Clin Endocrinol Metab 84 (1999) 435-439
41. Kudlacek S., Schneider B., Woloszczuk W., Pietschmann P., and Willvonseder R. Austrian Group on Normative Values of Bone Metabolism. Serum levels of osteoprotegerin increase with age in healthy adult population. Bone 32 (2003) 681-686
42. Indridason O.S., Franzson L., and Sigurdsson G. Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 16 (2005) 417-423
43. Mazziotti G., Sorvillo F., Piscopo M., et al. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin in postmenopausal women monitored for differentiated thyroid carcinoma. J Bone Miner Res 20 (2005) 480-486
44. Regalbuto C., Alagona C., Maiorana R., et al. Acute changes in clinical parameters and thyroid function peripheral markers following L-T4 withdrawal in patients totally thyroidectomized for thyroid cancer. J Endocrinol Invest 29 (2006) 32-40
45. Muratami T., Yamamoto M., Ono K., et al. Transforming growth factor-beta 1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 252 (1998) 747-752
46. Saika M., Inoue D., Kido S., and Matsumoto T. 17Beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 142 (2001) 2205-2212
47. Lee S.K., and Lorenzo J.A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cells formation. Endocrinology 140 (1999) 3552-3561
48. Hofbauer L.C., Gori F., Riggs B.L., et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140 (1999) 4377-4381
49. Szulc P., Hofbauer L.C., Heufelder A.E., Roth S., and Delmas P.D. Osteoprotegerin serum levels in men: correlation with age, estrogen and testosterone status. J Clin Endocrinol Metab 86 (2001) 3162-3165
50. Rogers A., Saleh G., Hannon R.A., Greenfield D., and Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 87 (2002) 4470-4475
51. Kitazawa S., Kajimoto K., Kondo T., and Kitazawa R. Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. J Cell Biochem 89 (2003) 771-777
52. Dovio A., Data V., and Angeli A. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice?. J Endocrinol Invest 28 Suppl 10 (2005) 14-22
53. Pantazi H., and Papapetrou P.D. Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab 57 (2000) 125-129
54. Abe E., Marians R.C., Yu W., et al. TSH is a negative regulator of skeletal remodelling. Cell 115 (2003) 151-162
55. Cecoli F., Rubinacci A., Cavallero D., et al. Recombinant human TSH does not acutely change osteoprotegerin and receptor activator of nuclear factor ligand in differentiated thyroid carcinoma. J Endocrinol Invest 29 Suppl 4 (2006) 25